Net Product Revenue was Organogenesis Holdings’s largest product and service line in fiscal 2025, bringing in $1.06B of $1.06B (100%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Product Revenue | — | — | $811.03M | $907.28M | $1.06B | ||||||
| Advanced Wound Care | $181.90M | $844.46M | — | — | — | ||||||
| Surgical Sports Medicine | $14.33M | $57.32M | — | — | — | ||||||
| Surgical &Amp; Sports Medicine | — | — | — | — | — | ||||||
| Surgical & Sports Medicine | — | — | — | — | — | ||||||
| Grant Income | — | — | — | — | $2.28M | ||||||
| Total | $196.23M | $901.79M | $811.03M | $907.28M | $1.06B |
Organogenesis Holdings brought in $1.06B from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That is less than the $1.13B it reports by major customers, so these lines do not cover all of its revenue. Net Product Revenue was the largest at $1.06B (99.8%), ahead of Grant Income at $2.28M (0.2%).
Organogenesis Holdings began breaking out Net Product Revenue in fiscal 2023 and Grant Income in fiscal 2025. Organogenesis Holdings stopped reporting Advanced Wound Care ($844.46M in fiscal 2022) and Surgical Sports Medicine ($57.32M in fiscal 2022) as separate lines.
Advanced Wound Care was Organogenesis Holdings’s largest revenue line in fiscal 2025, bringing in $1.06B of $1.13B (94%).
| Major Customers | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Advanced Wound Care | $811.03M | $907.28M | $1.06B |
| Surgical Sports Medicine | $55.25M | $56.81M | $63.58M |
| Total | $866.28M | $964.09M | $1.13B |
Organogenesis Holdings brought in $1.13B from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 16.8% from $964.09M in fiscal 2024. Advanced Wound Care was the largest at $1.06B (94.4%), ahead of Surgical Sports Medicine at $63.58M (5.6%).
Compared with fiscal 2024, Advanced Wound Care grew 17.1% to $1.06B and Surgical Sports Medicine grew 11.9% to $63.58M. From fiscal 2023 to 2025, combined revenue from these revenue lines grew from $866.28M to $1.13B, a compound annual growth rate of 14.0%. Advanced Wound Care's share of the total rose from 93.6% to 94.4%.
As Previously Reported was Organogenesis Holdings’s largest revenue line in fiscal 2022, bringing in $196.23M of $194.23M (101%).
| Restatement | FY 2022 |
|---|---|
| As Previously Reported | $196.23M |
| Revision Of Prior Period, Adjustment | -$2.00M |
| Total | $194.23M |
Organogenesis Holdings brought in $194.23M from its two revenue lines in fiscal 2022, the year ended March 31, 2022. As Previously Reported was the largest at $196.23M (101.0%).
The total is net of Revision Of Prior Period, Adjustment, which took $2.00M off revenue in fiscal 2022.
Organogenesis Holdings (ORGO) reports its revenue by product and service, by major customers and by restatement. In fiscal 2025, Net Product Revenue was its largest product and service line, bringing in $1.06B (99.8% of the total), followed by Grant Income at $2.28M (0.2%).
Net Product Revenue was Organogenesis Holdings' largest product and service line in fiscal 2025, bringing in $1.06B, or 99.8% of the $1.06B total across its two product and service lines.
Advanced Wound Care was Organogenesis Holdings' largest revenue line in fiscal 2025, bringing in $1.06B, or 94.4% of the $1.13B total across its two revenue lines.
Advanced Wound Care grew faster than Surgical Sports Medicine in fiscal 2025, up 17.1% from $907.28M to $1.06B. Surgical Sports Medicine grew 11.9% to $63.58M.
Every figure comes from Organogenesis Holdings' annual financial filings, as reported. Each line keeps the name Organogenesis Holdings gives it, and years follow its fiscal calendar.
Organogenesis Holdings' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.